Prevention and treatment of musculoskeletal disease in the haemophilia population: Role of prophylaxis and synovectomy

Haemophilia

Volumn 12, Issue SUPPL. 3, 2006, Pages 159-168

  Van den Berg, H M ^a   Dunn, A ^b   Fischer, K ^a   Blanchette, Victor S ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b EMORY UNIVERSITY   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Haemophilia; Prophylaxis; Synovectomy

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; YTTRIUM 90;

AGE; ANGIOGENESIS; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; FREQUENCY ANALYSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAXIMUM TOLERATED DOSE; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOTHERAPY; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SYNOVECTOMY; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

HEMARTHROSIS; HEMOPHILIA A; HUMANS; JOINT DISEASES; MALE; SYNOVIAL MEMBRANE;

EID: 33646149407     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01281.x     Document Type: Article

References (60)

1. Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
2. Ljung R. Meeting Report. Second Workshop of the European Paediatric Network for haemophilia management, 17-19 September 1998 in Vitznau/ Switzerland. Haemophilia 1999; 5: 286-91.
3. Yoshioka A, Taki M. International Forum. Prophylactic treatment of patients with haemophilia A or haemophilia B. Vox Sang 2005; 88: 62-7.
4. Blanchette P, Stain A, Rivard G et al. on behalf of the Association of Hemophilia Clinic Directors of Canada and the Canadian Association of Nurses in Hemophilia Care. A survey of factor VIII use in the Canadian hemophilia population. Haemophilia 2004; 10: 679-83.
5. Aledort L, Ljung R, Blanchette V on behalf of the International Prophylaxis Study Group (IPSG). Are randomized clinical trials (RCTs) the only truth? Not always. Journal of Thrombosis and Haemostasis 2006; 4: 503-4.
6. Huber M, Trattnig S, Lintner F. Anatomy, biochemistry, and physiology of articular cartilage. Invest Radiol 2000; 35: 573-80.
7. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg 1977; 59-A: 287-305.
8. Roosendaal G, van Rinsum AC, Vianen ME, van den Berg HM, Lafeber FPJG, Bijlsma JWJ. Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 1999; 34: 144-53.
9. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: Rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004; 10: 280-7.
10. Acharya SS, MacDonald DD, DiMichele DM et al. A role for angiogenesis in hemophilic synovitis. Blood 2004; 104: Abstract 42.
11. Madhok R, Bennett D, Sturrock RD, Forbes CD. Mechanisms of joint damage in an experimental model of hemophilic arthritis. Arthritis Rheum 1988; 31: 1148-55.
12. Roosendaal G, Vianen ME, Wenting MJG et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg 1998; 80-B: 540-5.
13. Morris CJ, Wainwright AC, Steven MM, Blake DR. The nature of iron deposits in haemophilic synovitis. Virchows Arch Pathol Anat 1984; 404: 75-85.
14. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl. 3): 117-21.
15. Glasson SS, Askew R, Sheppard B et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434: 644-8.
16. Nilsson IM, Berntorp E. Löfqvist T, Pettersson H, Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
17. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
18. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
19. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
20. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in hemophilia. Haemophilia 2004; 10: 629-48.
21. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
22. Price VE, Carcao M, Connolly B et al. A prospective longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J Thromb Haemost 2004; 2: 737-42.
23. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in-patients with haemophilia A and B start - the German experience. Haemophilia 1998; 4: 413-7.
24. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
25. Fischer K, van der Born JG, Mausar-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
26. Van Dijk K, Fischer K, van der Bom G, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: The role of the first joint bleed. Haemophilia 2005; 11: 438-43.
27. Feldman B, Rivard G, Israels S et al. Final results from the Canadian hemophilia dose escalation prophylaxis trial. J Thromb Haemost 2003; 1(Suppl. 1): Abstract 219.
28. Manco-Johnson MJ, Abshire TC, Brown D et al. Initial results of a randomized prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. Blood 2005; 106: Abstract 3.
29. van den Berg HM, Fischer K, van der bom JG, Roosendaal G, Mauser-Bunschoten EP. Effects of prophylactic treatment regimens in children with severe haemophilia: A comparison of different strategies. Haemophilia 2002; 8(Suppl. 2): 43-6.
30. Fischer K, van der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: Incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
31. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor VIII in deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
32. Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 24: 539-51.
33. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12.
34. Molho P, Rolland N, Lebrun T et al. and the French Study Group. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. Haemophilia 2000; 6: 23-32.
35. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: Where do we stand? Haemophilia 2004; 10(Suppl. 4): 97-104.
36. Fischer K, Astermark J, van der Bom JG et al. Prophylactic treatment for severe haemophilia: Comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
37. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
38. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American hemophilia treatment centres. Haemophilia 2003; 9(Suppl. 1): 19-26.
39. Montane I, McCollough NC, Chun-Yet Lian E. Synovectomy of the knee for hemophilic arthropathy. J Bone Joint Surg Am 1986; 68-A: 210-6.
40. Teigland JC, Tjonnfjord GE, Evensen SA, Charania B. Synovectomy for haemophilic arthropathy: 66-21 years of follow-up in 16 patients. J Intern Med 1994; 235: 239-43.
41. Journeycake JM, Miller KL, Anderson AM, Buchanan GR, Finnegan M. Arthroscopic synovectomy in children and adolescents with hemophilia. J Pediatr Hematol Oncol 2003; 25: 726-31.
42. Dunn AL, Busch MT, Wyly JB, Sullivan KM, Abshire TC. Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. J Pediatr Orthop 2004; 24: 414-26.
43. Tamurian RM, Spencer EE, Wojtys EM. The role of arthroscopic synovectomy in the management of hemarthrosis in hemophilia patients: Financial perspectives. Arthroscopy 2002; 18: 789-94.
44. Rivard GE, Girard M, Bélanger R, Jutras M, Guay J-P, Marton D. Synoviorthesis with colloidal 32 P chromic phosphate for the treatment of hemophilic arthropathy. J Bone Joint Surg 1994; 76-A: 482-8.
45. Siegel HJ, Luck JV, Siegel ME, Quionones C. Phosphate-32 colloid radiosynovectomy in hemophilia. Outcome in 125 procedures. Clin Orthop Relat Res 2001; 392: 409-17.
46. 32P radiosynoviorthesis in children with hemophilia. J Pediatr Hematol Oncol 2002; 24: 534-9.
47. Kavakli K, Aydoǧdu S, Omay B et al. Long-term evaluation of radioisotope synovectomy with Yttrium 90 for chronic synovitis in Turkish haemophiliacs: Izmir experience. Haemophilia 2006; 12: 28-35.
48. National Hemophilia Foundation. MASAC Recommendations Regarding Radionuclide Synovectomy. Document 163 http://www.hemophilia.org.
49. Silva M. Luck Jr JV, Llinás A. Chronic hemophilic synovitis: The role of radiosynovectomy. Treatment of Hemophilia. World Fed Hemophilia 2004; 33: 1-10.
50. Dunn AL, Busch MT, Wyly JB, Abshire TC. Radionuclide synovectomy for hemophilic arthropathy: A comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol. Thromb Haemost 2002; 87: 383-93.
51. Heim M, Tiktinsky R, Amit Y, Martinowitz U. Yttrium synoviorthesis of the elbow joints in persons with haemophilia. Haemophilia 2004; 10: 590-2.
52. Gedik, GK, Uǧur O, Atilla B, Dündar S. Is corticosteroid coinjection necessary for radiosynoviorthesis of patients with hemophilia ? Clin Nucl Med 2004; 29: 538-41.
53. Dunn AL, Manco-Johnson M, Busch MT, Balark K, Abshire TC. Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. J Thromb Haemost 2005; 3: 1541-2.
54. Caviglia HA, Fernandez-Palazzi F, Maffei E, Galatro G, Barrionuevo A. Chemical synoviorthesis for hemophilic synovitis. Clin Orthop Relat Res 1997; 343: 30-6.
55. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999: 5(Suppl. 3); 25-32.
56. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
57. Schramm W, Royal S, Kroner B et al. for the European Hemophilia Economic Study Group. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
58. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: A comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
59. Carlsson KS, Höjgård S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
60. Stobart K, Iorio A, Wu JK. Clotting Factor Concentrates Given to Prevent Bleeding and Bleeding-related Complications in People with Hemophilia A or B (Review). The Cochrane Collaboration. The Cochrane Library, Issue 3. John Wiley and Sons Ltd, 2005: 1-19.